Prevalence of hereditary antithrombin mutations is higher than estimated in patients with thrombotic events.
- Authors
- Fischer, Ronald; Sachs, Ulrich J; Heidinger, Kathrin S; Eisenburger, Dominik; Kemkes-Matthes, Bettina
- Year
- 2013
- Journal
- Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
- PMID
- 23429250
- DOI
- 10.1097/MBC.0b013e32835cc143
Antithrombin is the major inhibitor of blood coagulation, primarily inactivating thrombin and factor Xa. Inherited antithrombin deficiency is associated with an increased risk of thromboembolism. Its prevalence is estimated to be about 0.2% in the general healthy population, whereas it is 2% in patients with a history of thrombosis. We previously demonstrated thrombosis patients receiving therapeutic dosage of low-molecular-weight heparin having a lower antifactor Xa activity than originally estimated. In those patients, mutations in the AT gene (SERPINC1) were detected despite normal antithrombin activity. Thus we concluded that prevalence of antithrombin mutations might be higher than previously calculated. The aim of the present study was to investigate the prevalence of hereditary antithrombin mutations by analyzing the antithrombin gene in patients with a history of thromboembolism. Mutation analyses were performed by direct sequencing of SERPINC1 in 150 patients (aged <40 years) with thromboembolism and normal antithrombin levels. Patients with thrombophilic defects [factor V Leiden (G1691A), prothrombin (G20210T) mutation, protein C deficiency, protein S deficiency, and antiphospholipid antibodies] were excluded. The results were compared with those of 150 healthy controls without any personal history of thrombosis. Mutation analyses of all seven antithrombin exons revealed five (3.5%) patients with antithrombin mutations: three different heterozygous missense mutations were found in exon 2 and one (in two patients) in exon 7. Prevalence of inherited antithrombin mutations in thrombosis patients is higher than previously estimated. Functional antithrombin tests are unable to detect all clinically relevant antithrombin defects.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genomewide Association Study for Maximum Number of Alcoholic Drinks in European Americans and African Americans. | 2015 | 26036284 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| The Thromboembolism Heparinization and AntithrombiN Observational Study (THANOS-1). | Prucnal CK et al. | — | 2026 | → |
| Exploring antithrombin: insights into its physiological features, clinical implications and analytical techniques. | Saboor M et al. | — | 2024 | → |
| Hemostatic Challenges in Pediatric Critical Care Medicine-Hemostatic Balance in VAD. | Ghbeis MB et al. | — | 2021 | → |
| A series of 10 Polish patients with thromboembolic events and antithrombin deficiency: two new c.1154-1 G>C and c.1219-534 A>G SERPINC1 gene splicing mutations. | Wójcik M et al. | — | 2019 | → |
| SERPINC1 variants causing hereditary antithrombin deficiency in a Danish population. | Kjaergaard AD et al. | — | 2019 | → |
| Genetic Risk Factors in Venous Thromboembolism. | Hotoleanu C | — | 2017 | → |
| Recurrent mutations in a <i>SERPINC1</i> hotspot associate with venous thrombosis without apparent antithrombin deficiency. | Zeng W et al. | — | 2017 | → |
| Whole-exome sequencing in evaluation of patients with venous thromboembolism. | Lee EJ et al. | — | 2017 | → |
| Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. | Navarro-Fernández J et al. | — | 2016 | → |
| Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity. | Manlhiot C et al. | — | 2016 | → |
| Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency. | Kovac M et al. | — | 2016 | → |
| Genetic analysis should be included in clinical practice when screening for antithrombin deficiency. | Zeng W et al. | — | 2015 | → |
| Genomewide Association Study for Maximum Number of Alcoholic Drinks in European Americans and African Americans. | Xu K et al. | — | 2015 | → |
| Clinical and laboratory characteristics of paediatric and adolescent index cases with venous thromboembolism and antithrombin deficiency. An observational multicentre cohort study. | Limperger V et al. | — | 2014 | → |
| Identification of a new SERPINC1 mutation in a Kazak family that alters the heparin binding capacity of antithrombin. | Zheng H et al. | — | 2014 | → |
| Molecular basis and thrombotic manifestations of antithrombin deficiency in 15 unrelated Chinese patients. | Ding Q et al. | — | 2013 | → |